Abstract
The molecular mechanisms and gene regulatory networks sustaining cell proliferation in neuroblastoma (NBL) cells are still not fully understood. In this tumor context, it has been proposed that anti-proliferative drugs, such as the pan-HDAC inhibitor panobinostat, could be tested to mitigate tumor progression. Here, we set out to investigate the effects of panobinostat treatment at the unprecedented resolution offered by single-cell sequencing. We identified a global senescence signature paired with reduction in proliferation in treated Kelly cells and more isolated transcriptional responses compatible with early neuronal differentiation. Using master regulator analysis, we identified BAZ1A, HCFC1, MAZ, and ZNF146 as the transcriptional regulators most significantly repressed by panobinostat. Experimental silencing of these transcription factors (TFs) confirmed their role in sustaining NBL cell proliferation in vitro.
Funder
CARISBO Foundation
CINECA consortium
Italian Ministry of University and Research
Italian Association for Research on Cancer
Subject
Genetics (clinical),Genetics
Reference51 articles.
1. Neuroblastoma—Telomere Maintenance, Deregulated Signaling Transduction and Beyond;Stainczyk;Int. J. Cancer,2022
2. Ciaccio, R., De Rosa, P., Aloisi, S., Viggiano, M., Cimadom, L., Zadran, S.K., Perini, G., and Milazzo, G. (2021). Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs. Int. J. Mol. Sci., 22.
3. Methodological Advances in the Discovery of Novel Neuroblastoma Therapeutics;Segura;Expert Opin. Drug Discov.,2022
4. Molecular Biology of Neuroblastoma;Maris;JCO,1999
5. MYCN Function in Neuroblastoma Development;Otte;Front. Oncol.,2021
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献